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Abstract
Introduction Spontaneous reports of suspected adverse
drug reactions (ADRs) can be analyzed to yield additional
drug safety evidence for the pediatric population. Signal
detection algorithms (SDAs) are required for these analy-
ses; however, the performance of SDAs in the pediatric
population specifically is unknown. We tested the perfor-
mance of two SDAs on pediatric data from the US FDA
Adverse Event Reporting System (FAERS) and investi-
gated the impact of age stratification and age adjustment on
the performance of SDAs.
Methods We tested the performance of two established
SDAs: the proportional reporting ratio (PRR) and the
empirical Bayes geometric mean (EBGM) on a pediatric
dataset from FAERS (2004–2012). We compared the per-
formance of the SDAs with a published pediatric-specific
reference set by calculating diagnostic test-related statis-
tics, including the area under the curve (AUC) of receiver
operating characteristics. Impact of age stratification and
age-adjustment on the performance of the SDAs was
assessed. Age adjustment was performed by pooling
(Mantel-Hanszel) stratum-specific estimates.
Results A total of 115,674 pediatric reports (patients aged
0–18 years) comprising 893,587 drug–event combinations
(DECs) were analysed. Crude values of the AUC were
similar for both SDAs: 0.731 (PRR) and 0.745 (EBGM).
Stratification unmasked four DECs, e.g., ‘ibuprofen and
thrombocytopenia’. Age adjustment did not improve
performance.
Conclusion The performance of the two tested SDAs was
similar in the pediatric population. Age adjustment does not
improve performance and is therefore not recommended to
be performed routinely. Stratification can reveal new asso-
ciations, and therefore is recommendedwhen either drug use
is age-specific or when an age-specific risk is suspected.
Key Points
Detection of drug safety signals in children, who
represent a heterogeneous population, where age
may be a confounder or effect modifier, is an area in
which only limited research has been carried out.
The signal detection algorithms (SDAs) showed
good performance on pediatric data and can be
utilized for pediatric signal detection.
Age adjustment did not improve the performance of
the SDAs.
Age stratification showed that some signals may be
detected only in specific pediatric age groups. For
routine surveillance, checking for effect modification
across age strata may generate useful information.
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1 Introduction
Spontaneous reports of suspected adverse drug reactions
(ADRs) can yield important information regarding the
safety of drugs [1]. Usually, such reports are screened for
emerging safety issues by applying statistical methods
called signal detection algorithms (SDAs). Current SDAs
compare the reporting rate of a drug–event combination
(DEC) of interest with the expected count calculated from
the overall reporting rate of that reaction in the entire
database [1, 2]. Although SDAs are routinely applied to
reports pertaining to the general population, the perfor-
mance of SDAs in the pediatric population specifically has
not been investigated to date. Compared with adults, the
pattern of drug use and occurrence of ADRs in pediatric
patients may differ [3–5] since the latter population com-
prises a heterogeneous group of subjects at various stages
of development with age-dependent organ maturation and
hormonal changes [6]. Several studies investigating ADR
reporting in children have identified different reporting
patterns in this population than in adults [3, 5, 7, 8]. Since
ADRs may be age specific, adjustment for age seems to be
a logical step when investigating pediatric ADRs and has
been advocated by some researchers [4]. The major aim of
stratification is verification of confounding and effect
modification which otherwise may mask true signals [9].
Confounding by age can be dealt with by stratifying for age
categories and pooling stratum-specific estimates. How-
ever, if age-specific estimates differ (in case of effect
modification) pooling/adjustment should not be done;
instead, a verification of each individual stratum should be
performed. While stratification has been investigated by
some researchers [10], adjustment is routinely imple-
mented in some Bayesian but not in frequentist SDAs
[11–13]. Few studies have systematically addressed the
impact of age stratification or adjustment and the results are
contradictory [9, 14, 15].
Within the context of the Global Research in Pediatrics
(GRiP) Network of Excellence [16], we aimed to evaluate
the performance of two well-established SDAs in the
pediatric population and determine if age stratification or
adjustment impacts signal detection in this population.
2 Methods
2.1 Data Source
Data were retrieved from the publicly available version of
the US FDA Adverse Event Reporting System (FAERS),
which comprises spontaneous reports of suspected ADRs
submitted by manufacturers, healthcare professionals, and
patients. FAERS is one of the largest repositories of
spontaneous reports in the world [17, 18]. In this study, we
analyzed reports received from the first quarter of 2004
through to the third quarter of 2012.
For performance analysis, only reports of ADRs occur-
ring in children and adolescents (\18 years of age) were
retained. The ADRs in FAERS are coded according to the
Medical Dictionary for Regulatory Activities (MedDRA)
[19].
To improve the quality of the dataset, we excluded
reports with missing age, the main variable in our study.
Also, reports with reported age equal to zero and with a
MedDRA preferred term indicating prenatal exposure
were removed, as these imply in utero drug exposure and
were therefore not relevant for our study. We minimized
the number of duplicates (i.e., the same report submitted by
different reporters) by applying an algorithm based on case
identifier, report identifier, and drug and event names. For
multiple reports (i.e., the same report is reported at a later
time, with additional and updated information) [20], the
most recent (and most updated) report was retained for
analysis.
As drug names included in FAERS are not standardized,
a harmonization procedure was implemented. Briefly, this
consisted of removing superfluous characters and applying
a generalized edit distance matching algorithm [21] to map
free-text drug names to synonyms and finally to the cor-
responding active substance and World Health Organiza-
tion–Anatomic Therapeutic Chemical (WHO-ATC) code.
In this study, only those drugs reported as the primary or
secondary suspect in the FAERS database were retained for
analysis. Analysis was performed at DEC level, meaning
that within each report, every suspect drug was combined
with all reported ADRs. Thus, one report may comprise
more than one DEC.
2.2 Signal Detection Algorithms (SDAs)
We tested two well-established SDAs that are routinely
used by various national and international regulatory and/
or research institutions for signal detection: the propor-
tional reporting ratio (PRR) [2] and the empirical Bayes
geometric mean (EBGM) [13] (see Table 1). We also
tested count of reports as a positive control. In order to
define a signal of disproportionate reporting [22, 23], we
selected thresholds that are currently applied in routine
practice. We applied the SDAs at the end of the study
period, when the maximum number of reports had accrued.
2.3 Performance Assessment Measures
The performance of the SDAs was assessed by calculating
diagnostic test-related statistics, namely specificity and
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sensitivity, positive predictive value (PPV), and negative
predictive value (NPV) [24, 25]. Sensitivity is the ability of
the method to identify true signals correctly, while speci-
ficity is the ability to exclude false signals correctly. PPV
and NPV are posterior probabilities, describing how many
of the signals classified as positive or negative are indeed
correctly classified [24, 25].
Since diagnostic test-related statistics are dependent on
the threshold choice, their individual comparison has only a
limited, albeit practical, value. Therefore, we also esti-
mated the area under the curve (AUC) of receiver operating
characteristics (ROC) in order to compare the performance
of the SDAs [26]; the AUC incorporates both sensitivity
and specificity across all the possible values for a certain
SDA. Calculation of AUCs was conducted by varying only
the point estimate of each SDA and did not take into
account the other components of the SDA.
For the purpose of performance evaluation, a previously
constructed pediatric-specific GRiP reference set of posi-
tive and negative DECs was used. It consists of 37 positive
and 90 negative DECs and includes drugs that are admin-
istered to children and events that are regarded as important
for this population. The positive DECs are those that were
confirmed to occur based on evidence from Summary of
Product Characteristics (SmPC) and the published litera-
ture, while the negative DECs are those that could not be
confirmed at the time of literature review by either the
SmPC or the published literature. For a full description of
the reference set, see Osokogu et al. [27].
2.4 Stratification and Adjustment for Age
The impact of age stratification and adjustment on the
performance of the SDAs was investigated. First, we
checked for possible effect modification across age strata,
by stratifying the data according to age categories defined
by the International Conference on Harmonization (ICH)
[28] and calculating stratum-specific measures for each
SDA. Secondly, we calculated age-adjusted estimates for
PRR and EBGM by combining the stratum-specific esti-
mates in an overall measure [29]. The performance of each
SDA was reassessed after adjustment.
2.5 Statistical Analysis
Differences in the performance (AUC) of each SDA, crude
versus age-adjusted and crude versus count of reports (positive
control) were tested using paired chi-squared tests. Stratum-
specific contingency tables were tested for homogeneity using
the Breslow Day Tarone test [30]. The Mantel-Haenszel
approach was used for pooling and calculating age-adjusted
estimates [29]. The lower boundof theEBGM95 %confidence
interval (EBGM05)was calculated using the lower bound of the
95 % confidence interval (EB05) for each stratum and then
computing a Mantel-Haenszel average based on Zeinoun et al.
[31]. Statistical significance was defined by p\0.05.
Analysis was performed using SAS software version
9.2 (SAS Institute, Cary, NC, USA). Graphs were made in
SAS software version 9.2 and R version 3.1.3.
3 Results
3.1 Descriptive Analysis
For the study period (first quarter of 2004 through to the
third quarter of 2012), a total of 4,285,088 reports were
retrieved from FAERS. After eliminating duplicates
(n = 43,125) and removal of adult reports (n = 2,686,530)
and reports with missing age (n = 1,419,524) or age equal
to zero with a MedDRA preferred term indicating pre-
natal exposure (n = 20,235), 115,674 reports correspond-
ing to 893,587 individual DECs were retained for analysis
of pediatric spontaneous reports (see Table 2).
The total number of pediatric reports that included the
investigated drugs and ADRs from the reference set can be
observed in Fig. 1, which also shows data regarding adults
(for comparison purposes). The number of children
Table 1 Signal detection algorithms and corresponding thresholds applied
Signal detection algorithm Applied thresholda Institution where the method and the respective
threshold is currently used
Number of reports C5 NA
PRR PRR lower bound 95 % CI C1 and n C 5 reports European Medicines Agency (EMA)
EBGM EB05 CI C1.8, n C 3 reports, and EBGM C2.5 Medicines and Healthcare products
Regulatory Agency (MHRA)
CI confidence interval, EB05 lower bound of the 95 % confidence interval, EBGM empirical Bayes geometric mean, NA not available, PRR
proportional reporting ratio
a Thresholds were obtained from Candore et al. [23]
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exposed to the drugs of interest, for whom any of the
investigated ADRs was reported, varied from 26 patients
(for praziquantel) to 7535 patients (for ibuprofen), with a
median of 781 patients exposed across all drugs. The
number of events of interest in FAERS ranged from 164
reports (ventricular arrhythmia) to 14,777 (anaphylaxis),
with a median of 1004 reports across all events. For a more
detailed description of reports counts please refer to Elec-
tronic Supplementary material Table 1.
3.2 Overall Performance of SDAs
Both SDAs showed high specificity and low sensitivity.
They both had similar specificity values (PRR: 83.8 % and
EBGM: 91.9 %), while sensitivity was lower for EBGM
than for PRR (17.2 vs. 37.9 %). The NPV and PPV were
similar for both SDAs. When we applied the threshold-
independent (AUC-based) approach, the tested SDAs
showed similar performance in the pediatric population,
although the AUC value for EBGM (0.745) was slightly
higher than for PRR (0.731). None of the SDAs performed
better than the simple report count (AUC = 0.634;
p = 0.27 for PRR and p = 0.14 for EBGM)
3.3 Stratification and Adjustment for Age and its
Impact on Performance
Upon calculating SDA values per age stratum and testing
for heterogeneity across strata, we observed effect modi-
fication for some associations. Some false negatives (pos-
itive DECs that failed to be highlighted as signals when
analyzing data pertaining to the entire pediatric population)
were unmasked in some strata. Four DECs were unmasked
in total: ibuprofen–thrombocytopenia and isoniazid–sei-
zure (by PRR) and clarithromycin–erythema multiforme
and ibuprofen–erythema multiforme (by EBGM). Con-
versely, ‘ibuprofen–acute liver injury’, also a positive
DEC, was highlighted when we analyzed data pertaining to
the entire pediatric population, but it became clear after
stratifying that this DEC was highlighted only in older
children (adolescents) and not in younger children (see
Fig. 2). For an overview of SDA values across age strata
and results of heterogeneity tests please refer to Electronic
Supplementary Material Figures 1A and 1B.
We evaluated the performance of the methods within
individual age strata (see Table 3). On average, perfor-
mance of the SDAs was lower within age strata than in the
entire pediatric population and performance improved with
increasing stratum size. For infants and neonates, the per-
formance was very low, not better than chance (p[ 0.5 for
both SDAs). The adolescent group exhibited the best per-
formance, which was similar to the overall performance.
After adjusting for age by pooling the stratum-specific
estimates, the performance of the SDAs decreased,
although not significantly (see Fig. 3; crude vs. adjusted
AUC for PRR: 0.731 vs. 0.688, p = 0.267; crude vs.
adjusted AUC for EBGM: 0.745 vs. 0.683, p = 0.216).
4 Discussion
In this study, we have demonstrated that age stratification
for detection of drug safety signals in children may unmask
some signals that do not appear in either crude or adjusted
analysis. Adjustment for age does not improve perfor-
mance of the PRR and EBGM.
For the investigated events, similar reporting patterns
were observed for children and adults, while the investi-
gated drugs appeared to have different reporting patterns
(see Fig. 1). Different drug-related reporting patterns in
children versus adults have been reported previously [5].
Consequently, reported DECs for children may differ from
adults [3, 5], underlining the need for pediatric-specific
approaches to signal detection, especially when we con-
sider that reported drugs may vary by age group even
within the pediatric population [3, 32].
Overall, the PRR and EBGM showed good perfor-
mance, although results were slightly lower than results
reported on other (not pediatric-specific) reference sets
[32, 33]. The similarity in performance between PRR
and EBGM is in accordance with recent results from the
PROTECT (Pharmacoepidemiological Research on
Outcomes of Therapeutics by a European Consortium)
project [23]. The fact that the performance (based on
AUC) of PRR and EBGM was not statistically signifi-
cantly better than simple report count may be due to the
lack of power. Within age strata, performance seemed to
correlate with stratum size: the poorest results were
observed for infants and neonates (the smaller groups),
slightly improving for children, while the best perfor-
mance was observed for adolescents, the age stratum
with the highest number of tested DECs. Decrease in
power due to fewer reports and therefore DECs may
account for this observation. The fact that we used lower
bounds of confidence intervals for signaling instead of
point estimates might have exacerbated the influence of
sample size on the results, since smaller strata will have
Table 2 Description of pediatric reports by age categories
Age group Number of reports [n (%)]
Neonates: 0–27 days 5091 (4.40)
Infants: 28 days–23 months 12,566 (10.86)
Children: 2–11 years 49,982 (43.21)
Adolescents: 12–17 years 48,035 (41.53)
Total 115,674 (100)
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higher variability. In neonates and infants for whom
expected counts were difficult to calculate because of
few reports, we observed that simple report counts per-
formed similar or even better than the SDAs and might
be an alternative to commonly used SDAs. The fact that
simple report count performed better than SDAs may
have been because the reference set comprised known
DECs (which in turn may have influenced reporting)
rather than emerging safety issues, a hypothesis pro-
posed by Nore´n et al. [34].
Inspection of SDA values across child-specific strata
(age stratification) revealed some heterogeneity in esti-
mates, pointing to some effect modification. For example,
‘ibuprofen–thrombocytopenia’ was found as a signal in the
Fig. 1 Count of reports in the
pediatric and adult population
for the investigated adverse
drug reactions (a) and drugs (b),
cumulatively for the period
quarter 1 2004 to quarter 3
2012. The number of reports in
children is represented by bars
and plotted on the left axis,
while the number of reports in
adults is represented by the red
line and plotted on the right
axis; reports with missing age or
age = 0 were excluded. Only
reports mentioning any of the
drugs or events in the reference
set were considered
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adolescents’ group but not detected in the entire pediatric
population or the younger age categories. This suggests
that age-specific SDA calculations are sometimes needed,
rather than age-adjusted SDA estimates. The age-adjusted
estimates did not improve performance; in fact, even PPV
unexpectedly decreased. Simulation studies have shown
that when adjusted for strata, Bayesian methods such as
EBGM tend to be underestimated when there are sparse
strata [15]; this was also the case in our study. Previous
studies in adults show contradictory results, with some
showing a beneficial effect [9] while others did not [15].
The reason for our finding is not entirely clear; a possible
explanation is that age is not a strong confounder for the
investigated DECs. Also, the method of weighting (Mantel-
Haenszel approach) may have played a role since more
weight was assigned to age groups with more reports
(adolescents and children). This may have masked signals
occurring in age groups with fewer reports.
The limitations of data mining in FAERS include those
inherent to spontaneous reporting databases: under-report-
ing, lack of denominator data and control group, biases in
reporting, as well as missing and poor-quality data [35].
Missing information regarding age substantially reduced
the study sample size since we could not determine whe-
ther these reports described patients aged less than 18 years
old. While these biases are well acknowledged and have a
definite impact, they cannot be completely avoided.
Compared with adults, there are fewer reports and different
reporting patterns for children [3, 36, 37], which may
complicate signal detection in the pediatric population.
Evaluating performance of SDAs is a constant challenge
due to lack of standard methodologies, imperfect reference
standards, and uncertainty regarding the best thresholds
(see the Electronic Supplementary Material for measures of
performance using alternative thresholds). Some of the
drugs and events in the reference set are specific to one age
group within pediatrics and this is obvious in Fig. 1, even
though the reference set was designed to be relevant for the
entire pediatric population. We acknowledge that the ref-
erence set used, although specifically constructed for this
p-values were calculated with Breslow Day Tarone test for homogeneity
p<0.0001 p=0.001 p=0.339
Fig. 2 Variation of proportional reporting ratio and empirical Bayes geometric mean estimates across pediatric specific strata—selected
examples. EBGM empirical Bayes geometric mean, PRR proportional reporting ratio, SDA signal detection algorithm
Table 3 Performance of signal detection algorithms across age strata
Age groups and signal
detection algorithms
Size of the age stratum
(number of reports)
AUC
Neonates 5091
Number of reports 0.625
EBGM 0.600
PRR 0.65
Infants 12,566
Number of reports 0.667
EBGM 0.548
PRR 0.554
Children 49,982
Number of reports 0.654
EBGM 0.698
PRR 0.649
Adolescents 48,035
Number of reports 0.698
EBGM 0.771
PRR 0.718
Entire pediatric population
Number of reports 115,674 0.634
EBGM 0.746
PRR 0.733
AUC area under the curve, EBGM empirical Bayes geometric mean,
PRR proportional reporting ratio
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purpose, does not include all the ADRs that are highly
specific for pediatrics. This highlights the need for pedi-
atric-specific approaches to signal detection, accounting for
not just the entire pediatric population but also the different
age strata within pediatrics. Still, the reference set captures
various drug use and ADRs patterns [38] and is currently
the only available pediatric-specific reference set. The
thresholds applied to define a signal were obtained from
previous publications and other cut-off points may generate
better results; further research on pediatric-specific
thresholds should be encouraged.
5 Conclusion
Our study revealed that age adjustment did not improve the
performance of the SDAs. However, stratification revealed
some variation in the values of SDAs across strata (effect
modification) and inspection of stratum-specific estimates
might sometimes yield useful information during routine
surveillance.
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SDA Sensitivity Specificity PPV NPV AUC p-valueb
Number of reports  58.62 67.57 58.62 67.57 0.634 reference
PRR 37.93 83.78 64.71 63.27 0.731 0.266
EBGM 17.24 91.89 62.50 58.62 0.745 0.144
After age 
adjustment a
(reference-
crude 
PRR/EBGM)
PRR 34.48 86.49 66.67 62.75 0.688 0.267
EBGM 10.34 97.30 75.00 58.06 0.683 0.216
SDA-signal detection algorithm; PRR= Proportional reporting ratio; EBGM= Empirical Bayes Geometric Mean; AUC=area 
under the curve; PPV=positive predictive value; NPV-negative predictive value
a adjusted PRR/ROR values calculated by combining the individual estimates from each age stratum into one measure 
according to the Mantel-Haenszel approach.
b paired chi-square test 
Fig. 3 Performance of signal
detection algorithms within the
entire pediatric population
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